Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT HOUSE: EPX-100 adjunctive therapy in Lennox-Gastaut syndrome
CTR20260854Phase 3Active
- Sponsor
- National Institute on Aging
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing EPX-100 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent change in CMMS-28 from baseline to end of the double-blind period. Started Jun 2026; status: active.
02
Drugs
clemizole
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on CTR20260854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260854.